Hints and tips:
...The Alizyme administration was followed just one week later by that of York Pharma, a dermatology biotech group....
...- Corporate: Alizyme, Coffee Republic, Mears, St Modwen, Ultimate Finance, Moneysupermarket.com, EasyJet, Central African Mining....
...- Corporate: Rolls-Royce, Asos, Premier Foods, Informa, Hargreaves Lansdown, SDL, Cobham, Serco, Senior, Alizyme....
...Two potential players stand out as interesting plays for adventurous types – Alizyme and Renovo....
...Alizyme lost 3.5 per cent to 75p in spite of a licensing deal with Prometheus Laboratories of the US for the biopharmaceutical group’s treatment for gastrointestinal diseases....
...Evolution Securities said that Oxford BioMedica, down 4.2 per cent to 28p, Alizyme, off 6.3 per cent to 137¼p, and Neutec Pharma, 0.2 per cent softer at 490½p, were all possible targets....
...Drug developer Alizyme gained 10.1 per cent to 111¼p after a positive trial of its anti-obesity drug Cetilistat in the US. Carpathian Resources dropped 23.5 per cent to 2.87p....
...Alizyme added 6.4 per cent at 91½p on speculation that several hedge funds were forced to short-cover their positions after its recent placing and open offer to raise £32m....
...Alizyme rose 13.2 per cent to 129p after Merrill Lynch initiated coverage with a “buy” rating and said the biotech company was a potential bid target....
International Edition